To determine the objective response rate (ORR; complete response + partial response) in pediatric patients treated with ensartinib with advanced solid tumors (including CNS tumors), non-Hodgkin lymphomas or histiocytic disorder that harbor ALK or ROS1 functions or that harbor ALK missense mutations.
Creatine is one of the most studied supplements with research demonstrating its efficacy in augmenting training adaptations such as improved strength and physical function in a variety of healthy and clinical populations. Given the additive effects of creatine and exercise improving muscle performance and lean body mass, it is not surprising that creatine is being explored as a cancer therapeutic to improve survivorship. However, the paucity of research in this area stems from the lack of awareness of the potential role of creatine supplementation in cancer survivors. Therefore, the purpose of this project is to test the hypothesis that creatine will accelerate adaptations associated with exercise in cancer survivors that are engaged in the Thrivewell exercise program.
This partially randomized phase III trial is studying maintenance chemotherapy to see how well it works compared to observation following induction chemotherapy and radiation therapy in treating young patients with newly diagnosed ependymoma. Drugs used in chemotherapy, such as vincristine sulfate, carboplatin, cyclophosphamide, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Giving chemotherapy with radiation therapy may kill more tumor cells and allow doctors to save the part of the body where the cancer started.
The purpose of this study is to evaluate the effectiveness of ProstAtak® immunotherapy in patients undergoing active surveillance for localized prostate cancer. ProstAtak® involves the use of aglatimagene besadenovec (AdV-tk) to kill tumor cells and stimulate a cancer vaccine effect. Killing tumor cells in an immune stimulatory environment induces the body's immune system to detect and destroy cancer cells. ProstAtak® has been well tolerated in previous trials in patients with prostate cancer and other tumor types. Biochemical, pathologic and immune responses have been demonstrated in newly diagnosed and recurrent prostate cancer. The hypothesis is that ProstAtak can lead to improvement in the clinical outcome for patients with prostate cancer. Participants will be randomized to the ProstAtak® or control arm at a 2:1 ratio. Both arms receive standard of care active surveillance evaluations.
The MPN-RC Research Tissue Bank plans to collect and store tissue specimens from patients with MPN including (polycythemia vera [PV], primary myelofibrosis [PMF], and essential thrombocythemia [ET]).These tissue samples will be used to conduct laboratory investigations within the laboratory-based scientific projects of the MPN-RC to help define mechanisms involved in the pathophysiology, progression and effects of treatment of myelofibrosis.